Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian Cancer.

(1) Background: The Genetic Counseling Satisfaction Scale (GCSS) is a widely used tool to evaluate patient satisfaction. To our knowledge, a validated French-language version of this tool is not yet available. This article reports on the cross-cultural adaptation and validation of a French version of the Genetic Counseling Satisfaction Scale (GCSS) to evaluate genetic counseling services for patient consultation in hereditary breast and ovarian cancer (HBOC). (2) Methods: The scale was culturally adapted following guidelines from Beaton et al. (2000). Cognitive interviews were conducted to ensure items were understood according to the intended meaning. The internal consistency, floor and ceiling effects, and testing of group differences were assessed using a sample of 172 patients who attended a pretest group genetic counseling session. (3) Results: Participants understood all items according to the intended meaning. The internal consistency was high for the total scale (0.90) and for the corrected item-to-total correlations (varying between 0.62 and 0.78). No floor or ceiling effects were observed. Group difference analyses generally followed expectations. (4) Conclusion: This process generated a French version of the GCSS that is clearly understood by patients, and has psychometric properties adequately in line those reported for its original English version.

A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.

Medical genetic services are facing an unprecedented demand for counseling and testing for hereditary breast and ovarian cancer (HBOC) in a context of limited resources. To help resolve this issue, a collaborative oncogenetic model was recently developed and implemented at the CHU de Québec-Université Laval; Quebec; Canada. Here, we present the protocol of the C-MOnGene (Collaborative Model in OncoGenetics) study, funded to examine the context in which the model was implemented and document the lessons that can be learned to optimize the delivery of oncogenetic services. Within three years of implementation, the model allowed researchers to double the annual number of patients seen in genetic counseling. The average number of days between genetic counseling and disclosure of test results significantly decreased. Group counseling sessions improved participants' understanding of breast cancer risk and increased knowledge of breast cancer and genetics and a large majority of them reported to be overwhelmingly satisfied with the process. These quality and performance indicators suggest this oncogenetic model offers a flexible, patient-centered and efficient genetic counseling and testing for HBOC. By identifying the critical facilitating factors and barriers, our study will provide an evidence base for organizations interested in transitioning to an oncogenetic model integrated into oncology care; including teams that are not specialized but are trained in genetics.

A retrospective analysis of airway management in patients with obstructive sleep apnea and its effects on postanesthesia care unit length of stay.

Obstructive sleep apnea (OSA) is a form of sleep-disordered breathing characterized by periods of partial or complete obstruction of the upper airway during sleep, resulting in oxygen desaturations. Symptoms and risk factors for OSA are of particular importance in the management of OSA patients in the perioperative setting. The present study collected data regarding the intraoperative airway management of OSA patients and their course in the postanesthesia care unit (PACU) over a six-month period. A total of 86 patients underwent general anesthesia, 63 of whom were intubated by direct laryngoscopy. Of these, 43% were classified as a grade 1 view by direct laryngoscopy, 43% were grade 2 and 14% were classified as grade 3. Apnea events or periods of desaturation in the PACU were observed in 27% of cases. Length of stay was significantly longer for cases in which PACU nurses had indicated that OSA had affected the individuals' postoperative course of treatment. Overall, OSA patients had an increased frequency of grade 3 views compared with the general population, and adjuncts were commonly used to help secure the airway in OSA patients. Symptomatic OSA patients placed increased demands on the PACU in terms of length of stay and hospital resources.

L'apnée obstructive du sommeil (AOS) est une forme de trouble respiratoire du sommeil caractérisée par des périodes d'obstruction partielle ou complète des voies respiratoires supérieures pendant le sommeil, qui provoque des désaturations en oxygène. Les symptômes et facteurs de risque d'AOS revêtent une importance particulière pour la prise en charge des patients atteints d'AOS en milieu périopératoire. La présente étude a permis de colliger, sur une période de six mois, des données sur la prise en charge intraopératoire et l'évolution des voies supérieures des patients atteints d'AOS à l'unité de soins posthanesthésique (USPA). Au total, 86 patients ont subi une anesthésie générale. De ce nombre, 63 ont été intubés par laryngoscopie directe, dont 43 % ont obtenu une vue de classe 1, 43 %, une vue de classe 2 et 14 %, une vue de classe 3. Dans 27 % des cas, les chercheurs ont observé des épisodes d'apnée ou de désaturation à l'USPA. La durée d'hospitalisation était beau-coup plus longue dans les cas où, selon les infirmières de l'USPA, l'AOS avait nui à l'évolution postopératoire du traitement. Dans l'ensemble, les patients atteints d'AOS présentaient davantage de vues de classe 3 que la population générale, et il fallait souvent utiliser des accessoires pour sécuriser leurs voies respiratoires. À l'USPA, les patients symptomatiques atteints d'AOS étaient hospitalisés plus longtemps et mobilisaient plus de ressources hospitalières.

Effects of battery type and age on performance of rechargeable laryngoscopes.

Optimal visualization of the glottis can be crucial to successful laryngoscopy. Limited information has been published on the light intensity delivered from laryngoscopes powered by rechargeable batteries. In this study the laryngoscope light intensity delivered from 10 nickel metal hydride (NiMH), 7 nickel cadmium (NiCAD), and 2 lithium (LI) batteries with 3-5 or more years of clinical usage were tested in comparison to 5 new NiMH batteries. Each battery was charged in a new laryngoscope handle and recharging unit for 24 h before testing. Light intensity (lux) from the bulb in the laryngoscope handle was recorded at 3-min intervals under continuous loading until battery depletion. The mean times ±1 standard deviation (SD) to minimum acceptable light output (2,000 lux from the handle) were new NiMH 70 ± 1 min, 3-year-old NiMH 96 ± 2 min, 5+ year-old NiCAD 45 ± 22 min, and 5+ year-old LI 117 ± 4 min. There were significant differences in the time to minimum light intensity among all groups (p = 0.00-0.04). All new and used batteries exceeded the minimum ISO standard of light intensity for more than 10 min. These data demonstrate that rechargeable laryngoscope batteries can safely be used for several years before requiring replacement.

Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.

BACKGROUND AND OBJECTIVE: In clinical settings with fixed resources allocated to predictive genetic testing for high-risk cancer predisposition genes, optimal strategies for mutation screening programmes are critically important. These depend on the mutation spectrum found in the population under consideration and the frequency of mutations detected as a function of the personal and family history of cancer, which are both affected by the presence of founder mutations and demographic characteristics of the underlying population. The results of multistep genetic testing for mutations in BRCA1 or BRCA2 in a large series of families with breast cancer in the French-Canadian population of Quebec, Canada are reported. METHODS: A total of 256 high-risk families were ascertained from regional familial cancer clinics throughout the province of Quebec. Initially, families were tested for a panel of specific mutations known to occur in this population. Families in which no mutation was identified were then comprehensively tested. Three algorithms to predict the presence of mutations were evaluated, including the prevalence tables provided by Myriad Genetics Laboratories, the Manchester Scoring System and a logistic regression approach based on the data from this study. RESULTS: 8 of the 15 distinct mutations found in 62 BRCA1/BRCA2-positive families had never been previously reported in this population, whereas 82% carried 1 of the 4 mutations currently observed in > or =2 families. In the subset of 191 families in which at least 1 affected individual was tested, 29% carried a mutation. Of these 27 BRCA1-positive and 29 BRCA2-positive families, 48 (86%) were found to harbour a mutation detected by the initial test. Among the remaining 143 inconclusive families, all 8 families found to have a mutation after complete sequencing had Manchester Scores > or =18. The logistic regression and Manchester Scores provided equal predictive power, and both were significantly better than the Myriad Genetics Laboratories prevalence tables (p<0.001). A threshold of Manchester Score > or =18 provided an overall sensitivity of 86% and a specificity of 82%, with a positive predictive value of 66% in this population. CONCLUSION: In this population, a testing strategy with an initial test using a panel of reported recurrent mutations, followed by full sequencing in families with Manchester Scores > or =18, represents an efficient test in terms of overall cost and sensitivity.